Recipharm establishes long term supply agreement with Tillotts Pharma AG
Recipharm, the contract development and manufacturing organisation (CDMO), announces that it has entered into a long term supply agreement with Tillotts Pharma AG.
The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol. The partnership will also involve the commercial scale development of Tillotts’ ongoing development programme for TP05. All products are part of Tillotts’ dedication to innovative pharmaceutical products in the field of gastroenterology.
Recipharm will provide advanced pellet coating technology for controlled release from its facility in Pessac, France, tablet and capsule manufacturing including final packaging from its facility in Fontaine, France, and bottle filling from its site in Lisbon, Portugal. The total shared investment across the Recipharm network to enable this business amounts to €3.5 million. This includes investments to create new capacity as well as product specific investments.
The collaboration between Recipharm and Tillotts Pharma AG marks an important step in Recipharm’s full service offering strategy, allowing customers to fulfil their needs for different technologies while working with Recipharm as one full service partner. This approach allows the CDMO to simplify both the technology transfer and scale-up of projects, as well as ongoing commercial supply.
Kjell Johansson, President Manufacturing Services Europe at Recipharm, said: “We are really pleased that Tillotts Pharma AG has chosen Recipharm for these exciting products and projects. Our technical solutions offer a high level of customisation and we look forward to working with Tillotts to ensure their continued development and success within the gastroenterology area.”
Mattias Norrman, COO of Tillotts Pharma AG, said: “We have undertaken a thorough evaluation process to ensure we partner with a CDMO that can meet the needs we have for project management during technology transfer and scale-up, as well as fulfilling our requirements as a reliable commercial supplier. We believe Recipharm is the ideal CDMO partner for this task and look forward to establishing a long term relationship.”
Kjell Johansson, President Manufacturing Services Europe, email@example.com, + 46 739 622620
For media enquiries, please contact Lindsay Baldry at ramarketing: firstname.lastname@example.org, + 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, Linkedin: /ramarketing
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and its services, please visit www.recipharm.com
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 250 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialization of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products AsacolTM and EntocortTM, as well as in-licensed products, in over 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
We invite you to visit our website www.tillotts.com.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03